Kura Oncology (KURA) Stock Price, Quote & News

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC;...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 500 8800

Website: kuraoncology.com

Address:

12730 High Bluff Drive, Suite 400, San Diego, United States

Nvidiagh Sep. 12 at 8:47 PM

$KURA what happened here ??

1 · Reply

bernardbaruch Sep. 12 at 8:08 PM

$KURA lol the criminal MM HF algo shenanigans in this ticker. Reloaded my 1000 may try to hang on this time.

0 · Reply

elmono Sep. 12 at 8:01 PM

$KURA F me….brutal sell off

0 · Reply

elmono Sep. 12 at 7:45 PM

$KURA could be collecting on sept call premiums

0 · Reply

elmono Sep. 12 at 5:19 PM

$KURA Armistice in big….could be just manipulating sp to acquire more 🤷‍♂️😂

0 · Reply

elmono Sep. 12 at 5:17 PM

$KURA $LRMR giving up a weeks gain like it was nothing…still a turd sector.

0 · Reply

redistributeW Sep. 12 at 4:40 PM

$KURA I'm thinking this heads back to 7s and then we get an approval late September early October. I'm not so sure about the tipifarnib esmo presentations

0 · Reply

elmono Sep. 12 at 3:56 PM

$KURA $LRMR $XBI choppy Friday in biotech country 🤷‍♂️

0 · Reply

FishinAround Sep. 12 at 3:40 PM

$KURA We have around 2.5 months until the 11/30 PDUFA date. I’m watching to see if this gap gets filled, plenty of time for it.

1 · Reply

elmono Sep. 12 at 2:01 PM

$KURA WTF…Friday turd? 💩 😂🤷‍♂️

1 · Reply

Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 5, 2025, 7:30 AM EDT - 7 days ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 3, 2025, 8:02 AM EDT - 9 days ago

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Aug 28, 2025, 7:30 AM EDT - 15 days ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Aug 9, 2025, 10:46 PM EDT - 4 weeks ago

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 weeks ago

Kura Oncology Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 6 weeks ago

Kura Oncology to Report Second Quarter 2025 Financial Results

Jul 2, 2025, 12:09 AM EDT - 2 months ago

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Jun 12, 2025, 7:30 AM EDT - 3 months ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Jun 2, 2025, 6:00 PM EDT - 3 months ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

$Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML$

Jun 1, 2025, 7:00 PM EDT - 3 months ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

May 22, 2025, 5:30 PM EDT - 4 months ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 14, 2025, 10:00 AM EDT - 4 months ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 6, 2025, 7:30 AM EDT - 4 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 1, 2025, 8:48 PM EDT - 4 months ago

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 4 months ago

Kura Oncology Reports First Quarter 2025 Financial Results

Apr 28, 2025, 7:30 AM EDT - 4 months ago

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Apr 24, 2025, 7:30 AM EDT - 5 months ago

Kura Oncology to Report First Quarter 2025 Financial Results

Apr 8, 2025, 7:30 AM EDT - 5 months ago

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Apr 1, 2025, 7:30 AM EDT - 5 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Mar 26, 2025, 7:30 AM EDT - 6 months ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Mar 4, 2025, 10:12 AM EST - 6 months ago

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Feb 27, 2025, 4:46 AM EST - 7 months ago

Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:03 PM EST - 7 months ago

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 7:30 AM EST - 7 months ago

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 6, 2025, 12:05 PM EST - 7 months ago

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

Feb 5, 2025, 4:01 PM EST - 7 months ago

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Jan 6, 2025, 4:30 PM EST - 8 months ago

Kura Oncology Announces Senior Executive Promotions

Dec 18, 2024, 1:46 PM EST - 9 months ago

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Dec 9, 2024, 7:00 AM EST - 9 months ago

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Dec 2, 2024, 7:30 AM EST - 10 months ago

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Nov 25, 2024, 7:30 AM EST - 10 months ago

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Nov 20, 2024, 5:52 PM EST - 10 months ago

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

Nov 20, 2024, 5:00 PM EST - 10 months ago

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Nov 9, 2024, 5:54 AM EST - 10 months ago

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 9:09 AM EST - 11 months ago

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Oct 31, 2024, 7:30 AM EDT - 11 months ago

Kura Oncology to Report Third Quarter 2024 Financial Results

Oct 29, 2024, 8:00 AM EDT - 11 months ago

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

Oct 24, 2024, 7:30 AM EDT - 11 months ago

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

Oct 23, 2024, 7:30 AM EDT - 11 months ago

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

Sep 30, 2024, 6:30 PM EDT - 1 year ago

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

Sep 17, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

Aug 9, 2024, 2:07 PM EDT - 1 year ago

Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Report Second Quarter 2024 Financial Results

Jun 24, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

Jun 11, 2024, 2:00 PM EDT - 1 year ago

Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community

May 29, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Participate in Jefferies Global Healthcare Conference

May 14, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

May 4, 2024, 5:28 PM EDT - 1 year ago

Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript

Nvidiagh Sep. 12 at 8:47 PM

$KURA what happened here ??

1 · Reply

bernardbaruch Sep. 12 at 8:08 PM

$KURA lol the criminal MM HF algo shenanigans in this ticker. Reloaded my 1000 may try to hang on this time.

0 · Reply

elmono Sep. 12 at 8:01 PM

$KURA F me….brutal sell off

0 · Reply

elmono Sep. 12 at 7:45 PM

$KURA could be collecting on sept call premiums

0 · Reply

elmono Sep. 12 at 5:19 PM

$KURA Armistice in big….could be just manipulating sp to acquire more 🤷‍♂️😂

0 · Reply

elmono Sep. 12 at 5:17 PM

$KURA $LRMR giving up a weeks gain like it was nothing…still a turd sector.

0 · Reply

redistributeW Sep. 12 at 4:40 PM

$KURA I'm thinking this heads back to 7s and then we get an approval late September early October. I'm not so sure about the tipifarnib esmo presentations

0 · Reply

elmono Sep. 12 at 3:56 PM

$KURA $LRMR $XBI choppy Friday in biotech country 🤷‍♂️

0 · Reply

FishinAround Sep. 12 at 3:40 PM

$KURA We have around 2.5 months until the 11/30 PDUFA date. I’m watching to see if this gap gets filled, plenty of time for it.

1 · Reply

elmono Sep. 12 at 2:01 PM

$KURA WTF…Friday turd? 💩 😂🤷‍♂️

1 · Reply

elmono Sep. 12 at 1:37 PM

$KURA

0 · Reply

Longterm007 Sep. 12 at 1:36 PM

$KURA

0 · Reply

Fiolek Sep. 12 at 1:16 PM

$KURA

0 · Reply

Oscarca Sep. 12 at 8:31 AM

$KURA

0 · Reply

Spd2base Sep. 11 at 2:36 PM

$KURA was expecting $OPEN movement here today 😂

0 · Reply

bernardbaruch Sep. 11 at 12:20 PM

$KURA started a little long premarket to swing. Nearly net/net balance sheet. Revenue generator. Pipeline. CEO buys. Catalysts. Magnificent cup with volume handle on the two year weekly. I don’t need a weatherman to tell me which way the wind is blowing. NIA

1 · Reply

kalpsik Sep. 11 at 7:02 AM

$KURA will we close the week above 9?

1 · Reply

TenYear Sep. 10 at 7:58 PM

$KURA refuses to close above 8.43

1 · Reply

blueb22 Sep. 10 at 7:47 PM

$BEAM $NTLA $SRPT $VKTX $KURA and many others with large short position -- Will crooks shorties and hedgies be able to keep their position open going into next week with 0.5% (or may be more) rate cut coming? (They will be burnt and running for cover if they do!) Also, rotation into good Biotechs which are undervalued is inevitable in next few days and weeks... Good Luck Longs 👍

0 · Reply

lukasgx Sep. 10 at 6:51 PM

$KURA good conference but didn’t see any better reaction than pre-conference

0 · Reply

mimiwor Sep. 10 at 3:15 PM

$KURA would you turn around asshole?

1 · Reply

Longterm007 Sep. 10 at 12:03 PM

$KURA Vamos 🚀

0 · Reply

Market Cap	765.98M
Revenue (ttm)	53.88M
Net Income (ttm)	-173.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-322.90%
Debt to Equity Ratio	0.03

Volume	1,582,200
Avg Vol	1,648,242
Day's Range	N/A - N/A
Shares Out	86.80M
Stochastic %K	32%
Beta	0.19
Analysts	Strong Sell
Price Target	$25.42